U.S. begins study on allergic reaction risk in Moderna, Pfizer vaccines


FILE PHOTO: Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) - The U.S. National Institutes of Health said on Wednesday it had begun a mid-stage study to determine the risk of allergic reactions to COVID-19 vaccines made by Moderna Inc and Pfizer Inc.

Several allergic reaction incidents, including serious episodes, known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.

In January, the U.S. Centers for Disease Control and Prevention said allergic reactions are occurring at a rate of 11.1 per 1 million vaccinations.

The study, funded by the National Institute of Allergy and Infectious Diseases, will enroll 3,400 adults between the ages of 18 to 69, with about 60% participants having a history of severe allergic reactions to food, insect stings or immunotherapy.

The goal of the trial is to access the proportion of participants who have a systemic allergic reaction within 90 minutes after injection.

The agency expects to report data later this summer.

(Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli, Bernard Orr)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
   

Next In World

Amnesty International to restore 'prisoner of conscience' status to Russia's Navalny: aide
Gulf states and Iran should agree on format for dialogue, says Qatari minister
Colombia sees calmer protests, industry groups warn of fuel shortages
Somalia revives ties with Kenya after nearly six-month break
U.S. bound-migrants vaccinated for COVID-19 in Mexican border city
Former Maldives president treated for wounds after blast outside home
Ousting hold-out regional governor, Congo's president tightens control
Police hold children in 'dire' conditions in Ethiopia's Oromiya: rights commission
Pentagon chief says removal of all contractors from Afghanistan under way
Immigration in focus at high level U.S.-Mexico talks on Friday

Stories You'll Enjoy


Vouchers